EGFR and colorectal carcinoma: In experimental murine colitis models, blockade of EGFR by the tyrosine kinase inhibitor gefitinib [14] or knockout of the EGFR [15] resulted in exacerbated colitis and colitis-driven colorectal carcinoma, indicating a crucial role of EGFR signaling cascades in intestinal tissue homeostasis.